{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17508", "batch_size": 260, "batch_pos": 127, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain a high-potency verb, potent metaphor, superlative + negative noun, or critical alert phrase.", "method": "llm_batch", "batch_id": "batch_2_6352", "batch_size": 260, "batch_pos": 106, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 3, "answer": "no", "rationale": "The segment describes scaling up testing, not impact using a moderate verb + scale.", "method": "llm_batch", "batch_id": "batch_3_2264", "batch_size": 260, "batch_pos": 86, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_13712", "batch_size": 260, "batch_pos": 73, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 5, "answer": "no", "rationale": "The segment reports scaling up testing, which is about capability/action, not explicit calming.", "method": "llm_batch", "batch_id": "batch_5_17252", "batch_size": 260, "batch_pos": 72, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_14324", "batch_size": 260, "batch_pos": 56, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_13384", "batch_size": 260, "batch_pos": 53, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
{"Q": 8, "answer": "yes", "rationale": "Describes scaling up testing as a capability without explicit reassurance.", "method": "llm_batch", "batch_id": "batch_8_7648", "batch_size": 260, "batch_pos": 236, "statement_text": "WastewaterSCAN, an infectious disease-tracking sewage surveillance network led by Stanford University and Emory University in partnership with Verily Life Sciences, has begun scaling up H5-specific testing of samples from all of its 190 sites at treatment plants across 36 states.", "article_id": 582}
